Ratings ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/06/2025 BST			5-day change	1st Jan Change
141.86 ^USD	-3.52%		+1.54%	-32.35%

05-23	Trump's Tariff Blitz Roils Markets, Targets EU and Apple
05-23	Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…

Highlights: ICON Public Limited Company

Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses: ICON Public Limited Company

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings Chart: ICON Public Limited Company

Source: Surperformance

ESG chart: ICON Public Limited Company

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	ICON PUBLIC LIMITED COMPANY				11.68B
	LONZA GROUP AG				49.38B
	IQVIA HOLDINGS INC.				27.55B
	CELLTRION, INC.				26.36B
	EUROFINS SCIENTIFIC SE				12.75B
	QIAGEN N.V.				10.28B
	MEDPACE HOLDINGS, INC.				8.65B
	Average				20.95B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes